Pro Vise Management Group, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Pro Vise Management Group, LLC

  • $1.25 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
BUY
$775.18 - $881.7 $36,433 - $41,439
47 Added 3.27%
1,486 $1.31 Million
Q3 2023

Nov 08, 2023
BUY
$692.45 - $844.37 $996,435 - $1.22 Million
1,439 New
1,439 $1.18 Million
Q3 2020

Oct 26, 2020
SELL
$544.75 - $658.21 $461,948 - $558,162
-848 Closed
0 $0
Q2 2020

Aug 07, 2020
BUY
$493.32 - $643.92 $418,335 - $546,044
848 New
848 $529,000
Q1 2020

May 07, 2020
SELL
$336.18 - $494.43 $205,069 - $301,602
-610 Closed
0 $0
Q4 2019

Feb 11, 2020
BUY
$274.13 - $376.51 $167,219 - $229,671
610 New
610 $229,000

Others Institutions Holding REGN

# of Institutions
1,497
Shares Held
82.8M
Call Options Held
1.22M
Put Options Held
1.51M
View Full List

About REGENERON PHARMACEUTICALS, INC.

REGN Quotes by TradingView
  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $73.4B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Pro Vise Management Group, LLC Portfolio

Follow Pro Vise Management Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Vise Management Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Vise Management Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email